SYNERA
LOE Approachinglidocaine; tetracaine
NDATOPICALPATCH
Approved
Jun 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNERA is a topical combination patch containing lidocaine and tetracaine, both local anesthetics used to provide dermal analgesia. It is applied to intact skin to reduce pain associated with needle-based procedures such as IV catheter placement and venipuncture. The dual-anesthetic formulation provides rapid onset and sustained numbing through transdermal penetration.
LOE Approaching
As a mature product approaching loss of exclusivity, SYNERA likely operates with a lean commercial team focused on defending market share against generic and competitive topical anesthetics.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYNERA offers limited career growth opportunity given its mature, LOE-approaching lifecycle and zero linked job openings. Roles are predominantly commercial-focused (sales, marketing) with emphasis on defending market share rather than innovation or expansion.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.